Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment

Retina. 2006 Mar;26(3):352-4. doi: 10.1097/00006982-200603000-00016.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Diabetic Retinopathy / complications
  • Diabetic Retinopathy / diagnosis
  • Diabetic Retinopathy / drug therapy
  • Female
  • Fluorescein Angiography
  • Humans
  • Injections
  • Iris / blood supply*
  • Middle Aged
  • Neovascularization, Pathologic / diagnosis
  • Neovascularization, Pathologic / drug therapy*
  • Neovascularization, Pathologic / etiology
  • Retinal Neovascularization / diagnosis
  • Retinal Neovascularization / drug therapy*
  • Retinal Neovascularization / etiology
  • Vascular Endothelial Growth Factor A / immunology
  • Vitreous Body

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab